


Regulation of phospholipid distribution in the lipid bilayer by flippases and scramblases

In the format provided by the
authors and unedited

Supplementary Information



Supplementary information Fig. 1. **Alignment of P4-ATPases that work as a flippase in the plasma membranes and endosomes.** (a) The amino acid sequences of the regions spanning the transmembrane helices α1, α2, α4, and α6, of human ATP8A1 (UniProt: Q9Y2Q0), 8A2 (Q9NTI2), 11A (P98196), 11C (Q8NB49), 10A (O60312), 10B (O94823), and yeast Dnf1 (P32660) are aligned to obtain the maximum homology. The residues that are identical in 5 or more members are red. The conserved “PVSM” motif that seems to work as a ‘gate’ is highlighted in green in ATP11C¹. The replacement of Q84 by Glu in ATP11A (highlighted in purple) concurs with the molecule flip of PtdSer and PtdCho². The amino acids that coordinate the serine residue of PtdSer in ATP11C are highlighted in dark green². The amino acid residues necessary for the flipping activity of ATP8A2³ are highlighted in yellow, while the residues proposed to determine the substrate specificity in ATP8A1^{4,5} are in light blue. The residues coordinated in the entry site (Q610 and S611) or exit site (R264, Y633, T648, and W-652) of the yeast Dnf1⁶ are highlighted in red. (b) The amino acid

sequences of the C-terminal region of the human members are aligned, and the homologous residues are in orange. The acidic di-leucine motif ([DE]XXXL[LI]) for endosome sorting⁷ is highlighted in green.

16C (327) IRKLINNGSYIAAFPHEGAYKSSQPIKTHGPQNNRHLLYERWARWGMWYKHQPLDLIRLYFGEKIGLYF
 16E (237) IERLLNSNTYSSAYPLHDGQYWKP--SEPPNPTNERYTHQNWARFSYFYKEQPLDLIKNYYGEKIGIYF
 16F (232) INRLVNSGIYKAAFPLHDCKFRQ--SEDPSCPNERYLLYREWHAHPRSIIYKKQPLDLIRKYGEKIGIYF
 16K (158) LRRLLTSGIVIQVFPLHDSEALKK-----LEDTWYT-RFALKYQPIDSIIRGYFGETIALYF

α1

16C (397) AWLQWYTGMLIPAAIVGLCVFFYGLFTMNNSQVSQEICAT---EVFMCPLCDKNCSLQRLNDSCIYAKV
 16E (305) VFLGFYTEMLFFAAVVGLACFIYGLLSMEHNSTSTEICDPEIGGQMIMCPLQDQVDYWRNLNSTCLASKF
 16F (300) AWLGYTQMLLLAAVVGACFLYGYLNQDNCTWSKEVCHPDIGGKIIMCPQCDRLCPFWKLNITCESSKK
 16K (213) GFLEYFTFALIPMAVIGLPYYLFVWE-----

α2

16C (464) TYLFDNGGTVFFAIFMAIWAIVFLEFVKRRRSILTYTWDLIEWEEEEETLRPQFEAKYYKMEIVNPITGK
 16E (375) SHLFDNESTVFFAIFMGIWVTLFLEFWKQROARLEYEWDLVDFEEEQQLQLREFEAMCKHRKLNNAVTK
 16F (370) LCIFDSFGTLVFAVFMGVWVTLFLEFWKRRQAELEYEWDVELQOEQA--RPEYEARCHTHVVINEITQE
 16K (239) ----DYDKYVIFASFNLIWSVILELWKRGCANMTYRWGTLLMKRKFEE-PRPGFHGV--LGINSITGK

α3

16C (534) PE--PHQPS SDKVTRL LVS VSGIFFMISLVITAVFGVVVYRLVMEQFASFK-----WNFIKQYWQF
 16E (446) MEP-YMP LYTRIPWYFLSGATVTL-WMSLVVTSMAVIVYRLSVFATFASFME SDAS-LKQVKSF LTPQI
 16F (438) EERIPFTAWGKCIRITLCASAVFF-WILLIIASVIGIIVYRLSVFIVFSAKL PKNINGTDPIQKYLTPTQT
 16K (301) EEP LY---PSYKRQLRIYLVSLP FVCLCLYFSLYVMMIYFDMEVWALGLHENS-----SEWTS

α4

α5

16C (594) ATSAAAVCINFIIMLLNLAYEKIAYLLTNLEYPRTESEWENSFALKMFLFQFVNLSNSSFYIAFFLGRF
 16E (513) TTSLTGSCNLFIIVILILNFFYEKIS-AITKMEIPRTYQEYESSLTLKMFLFQFVNLYSSCFYVAFKGF
 16F (507) ATSITASIISFIIMILNTIYEKVAIMITNFELPRTQTDYENSLTMKMFLFQFVNLYSSCFYIAFFKGF
 16K (357) VLLYVPSIIYAIVIEIMNRLYRYAAEFLTSWENHRLLESAYQNHILKVLVFNFLNCFASLFYIAFVLKD-

α6

16C (664) VGHPGKYNKLFDRWRL EECHPSGCLIDLCLQMGVIMFLKQIWNFMELGYPLIQNWWSRHKIKRGIH---
 16E (583) VGYPGKYTYL FNEWSEECDPGGCLIELTTLTIIMTGKQIFGNIKEAIYPLALNWWRRKARTNSE---
 16F (577) VGYPGDPVYWL GKYRNEECDPGGCLLELTTLTIIMGGKAIWNNIQEVLLPWIMNLIGRFHRVSGSE---
 16K (426) -----MKLLRQSLATLLITSQILNQIMESFLPYWLQRKHGVRVKRQVQALK

α7

α8

16C (731) ---DASIPQWENDWNLQPMNLHGLMDEYLEMVLQFGFTTIFVAAPFLAPLLALLNNIIEIRLDAYKFVVTQ
 16E (650) ----KLYSRWEQDHDLESFGPLGLFYFYLETVTQFGFVTLFVASFPLAPLLALINNIVEIRVDWAKLTTQ
 16F (644) ----KITPRWEQDYHLQPMGKGLGLFYFYLEMIIQFGFVTLFVASFPLAPLLALVNNIIEIRVDWAKLTTQ
 16K (472) ADIDATLYEQVILEKEMGTY-LGTFDDYLELFLQFGYVSLFSCVYPLAAAFVLLNNFTEVNSDALKMCRV

α9

16C (798) WRRPLPARATDIGIWLGILEGIGILAVITNAFVIAITSDYIPRFVYEYKYGPCANHVEPSENCLKGYVNN
 16E (716) YRRTVASKAHSIGVWQDILYGMVLSVATNAFIVAFTSDIIPRLVYYYAYST-----NATQPM TGYVNN
 16F (710) FRRLVPEKAQDIGAWQPI MQGIAILAVVTNAMI IAF TSDMIPRLVYYWSFSVPP-YGDHTSYTMEGYINN
 16K (541) FKRPFPSEPSANIGVWQLAFETMSVISVVTNCALIGMSPQV-----

α10

16C (868) SLSFFDLSEL-----GMGKSGY-----CRYRDYRGPPWSSKPYEFTLQYWHILAARLAFIIVFEHLVFGI
 16E (780) SL SVFLIADFPNHTAPS EKRDF--ITCRYRDYRYPPDDENKVFHNMQF WHVLA AKMTFIIVMEHV VFLV
 16F (779) TLSIFKVADFKNKS KGNPYSDLG NHTTCRYRDFRYPPGHPQEYKHNIIYWHVIAAKLAFIIVMEHVIYSV
 16K (581) -----NAVFPESKADLILIVVAVEHALLAL

16C (928) KSFIAYLIPDVPKGLHDIRREKYL VQEMMYEAELEHLQQORRKS GQPVHHEWP-----
 16E (847) KFLLAWMIPDVPKDVVERIKREKLMTIKILHDFELNKLKENLGINSN EFAKHVMIEENKAQLAKSTL
 16F (849) KFFISYAIPDVSKRTKSKI QREKYL TQKL LHENHLKDMTKNMGVIAERMIEAVDNNLRPKSE-----
 16K (606) KFILAFAIPDKPRHIQMKLARLEFESLEALKQQQMKLV TENLKEEPMESGKEKAT-----

Supplementary Fig. 2. **TMEM16 Ca²⁺-dependent scramblase.** The amino acid sequences of human TMEM16C (UniProt: Q9BYT9), 16E (UniProt: Q75V66), 16F (Q4KMQ2), and 16K (Q9NW15) are aligned. The residues identical among the three or four members are shown in red. The transmembrane helices are shadowed and numbered. The number at the right is the amino acid number. The acidic residues involved in Ca²⁺ -binding are highlighted in yellow. In addition to the well-accepted five Glu/Asp residues (Glu-623, Glu-666, Glu-670, Glu-698, and Asp-702) in helices α 6-8 of human TMEM16F) that bind two Ca²⁺ (^{8,9}), Glu-394 in α 2 and Asp-858 in α 10 coordinate an additional Ca²⁺ (^{10,11}). The domain responsible for scrambling phospholipids^{12,13}, assigned in TMEM16F, is highlighted in light blue. The replacement of Phe-518 or Tyr-563 (highlighted in green) by Lys in TMEM16F concurs with the mutant constitutive-active¹⁴. The gain-of-function mutations of TMEM16C found in dystonia (N225S, Y279N, I308L, G400V, V463M, W490C, R494W, E510K, A657T, Y847C) (<https://www.hgmd.cf.ac.uk/>) and TMEM16E (R215G, C356R/G/Y, C360Y, S500F, T513I, and G518E) found in gnathodiaphyseal dysplasia¹⁵ are highlighted in green. The mutations of N52S, F54S, R57W, R58W, D81G, V87I, D93E, L108R, G126V, I133F, H134R/Y, Y143C, E202K, R215G, G231V, K259N, N265S, P266L, L273F, G301V, C342Y, N366S, T368M, R404L, A432G, A464D, M470R, S506G, M543I, R547Q, T548I, S555I, Q564L, F578S, R642L, Y652C, W655C, Y673C, N701D, T714S, R758C, L781P, S796L, C804S, Y806C, Y819C, A830V, M833K, M839R, H841D, and I865L (<https://www.hgmd.cf.ac.uk/>) (highlighted in pink) in TMEM16E are loss of function mutations causing muscular dystrophy or myopathy¹⁵. Mutations of F171S, G229W, R263H, F337V, L510R, C513R, and D615Q (<https://www.hgmd.cf.ac.uk/>) (highlighted in pink) in TMEM16K were found in human spinocerebellar ataxia¹⁶.

(R222G, C294R, and E327K) (<https://www.hgmd.cf.ac.uk/>)¹⁸, and the residues mutated in *C. elegans* (G76E, S94L, G139R, G200E, A309T, and E356K)¹⁹ are highlighted in purple. The number at the bottom line is the amino acid position of human XKR9.

		$\alpha 1$		$\alpha 2$		
XKR8-N	MPWSSRGALLR	DLVLGVLG	TAAFLLDL	GTDLWAAV-QYALG	GRYLWAAVL	LALLGLASVA 59
XKR8-C	-----	KPLLGLGSS	SVIYFLWN	LLLLWPRVLA	VALEFSA	LFPSYVALHFLGL---W 237
		$\alpha 6$		$\alpha 7$		
		$\alpha 3a$		$\alpha 3b$		
XKR8-N	LQLFSWLWLR	ADPAGLHGSQ	PPRCLALLHLL	QLGYLYRCV	QELRQGLLVW	QQEEPSEFD 119
XKR8-C	LVLLLWVWLQ	GTDFMPDP	SSEWLYRV	TVATILYFSW	-FNVAEGRTR	GRAIHH-----FA 290
		$\alpha 8$				
	$\alpha 4a$		$\alpha 4b$		$\alpha 5$	
XKR8-N	LAYADFLALD	ISMLRFL	ETFL	ETAPQLTLVLA	IMLQSGRAEYYQW	VGICTSFLGISWALL 179
XKR8-C	FLLSDSILL-	VATWVTHSS	SWLPSGIP	LQLWLP-----	VGCGCF	FLGLALRLV 336
	$\alpha 9$				$\alpha 10$	
XKR8-N	DYH	RALR	TCLPS	-----		191
XKR8-C	YH	WLHP	SCC	WKPD	PDQVDG	ARSLLSPEGYQLPQNRRMTHLAQKFFPKAKDEAASPVKG 395

Supplemental Fig. 4. **Two similar domains in human XKR8.** The amino acid sequences of the N-terminal (amino acids 1-191) and C-terminal (amino acids 192-395) domains of human XKR8 (UniProtKB; Q9H6D3) are aligned. The identical amino acids are red, while the conserved amino acids are orange. The caspase 3-recognition site is highlighted in yellow, while the charged amino acids essential for XKR8's scrambling activity are green.

References

1. Nakanishi, H. *et al.*, Transport cycle of plasma membrane flippase ATP11C by cryo-EM. *Cell Rep.* **32**, 108208 (2020).
2. Segawa, K. *et al.*, A sublethal ATP11A mutation associated with neurological deterioration causes aberrant phosphatidylcholine flipping in plasma membranes. *J. Clin. Invest.* **131**, e148005 (2021).
3. Vestergaard, A. L. *et al.*, Critical roles of isoleucine-364 and adjacent residues in a hydrophobic gate control of phospholipid transport by the mammalian P4-ATPase ATP8A2. *Proc. Nat. Acad. Sci. USA* **111**, E1334-1343 (2014).
4. Baldridge, R. D. & Graham, T. R., Two-gate mechanism for phospholipid selection and transport by type IV P-type ATPases. *Proc. Natl. Acad. Sci. USA* **110**, E358-367 (2013).
5. Hiraizumi, M., Yamashita, K., Nishizawa, T., & Nureki, O., Cryo-EM structures capture the transport cycle of the P4-ATPase flippase. *Science* **365**, 1149-1155 (2019).
6. Bai, L. *et al.*, Transport mechanism of P4 ATPase phosphatidylcholine flippases. *eLife* **9**, e62163 (2020).
7. Kelly, B. T. *et al.*, A structural explanation for the binding of endocytic dileucine motifs by the AP2 complex. *Nature* **456**, 976-979 (2008).
8. Brunner, J. D., Lim, N. K., Schenck, S., Duerst, A., & Dutzler, R., X-ray structure of a calcium-activated TMEM16 lipid scramblase. *Nature* **516**, 207-212 (2014).
9. Ishihara, K., Suzuki, J., & Nagata, S., Role of Ca²⁺ in the stability and function of tmem16F and 16K. *Biochemistry* **55**, 3180-3188 (2016).
10. Bushell, S. R. *et al.*, The structural basis of lipid scrambling and inactivation in the endoplasmic reticulum scramblase TMEM16K. *Nat. Commun.* **10**, 3956 (2019).
11. Alvadia, C. *et al.*, Cryo-EM structures and functional characterization of the murine lipid scramblase TMEM16F. *eLife* **8**, e44365 (2019).
12. Gyobu, S., Ishihara, K., Suzuki, J., Segawa, K., & Nagata, S., Characterization of the scrambling domain of the TMEM16 family. *Proc. Nat. Acad. Sci. USA* **114**, 6274-6279 (2017).
13. Yu, K. *et al.*, Identification of a lipid scrambling domain in ANO6/TMEM16F. *eLife* **4**, e06901 (2015).

14. Le, T. *et al.*, An inner activation gate controls TMEM16F phospholipid scrambling. *Nat. Commun.* **10**, 1846 (2019).
15. Chandra, G. *et al.*, Dysregulated calcium homeostasis prevents plasma membrane repair in Anoctamin 5/TMEM16E-deficient patient muscle cells. *Cell Death Discov.* **5**, 118 (2019).
16. Chrysanthou, A., Ververis, A., & Christodoulou, K., ANO10 function in health and disease. *Cerebellum* <https://doi.org/10.1007/s12311-022-01395-3> (2022).
17. Sakuragi, T. *et al.*, The tertiary structure of the human Xkr8–Basigin complex that scrambles phospholipids at plasma membranes. *Nat. Struct. Mol. Biol.* **28**, 825-834 (2021).
18. Jung, H. H., Danek, A., Walker, R. H., Frey, B. M., & Gassner, C. McLeod neuroacanthocytosis syndrome in *GeneReviews*, edited by Margaret P. Adam *et al.* (U.S. National Library of Medicine, Seattle, USA, 2019), pp. <https://www.ncbi.nlm.nih.gov/books/NBK1354/>.
19. Stanfield, G. M. & Horvitz, H. R., The ced-8 gene controls the timing of programmed cell deaths in *C. elegans*. *Mol. Cell* **5**, 423-433 (2000).